中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

73 records (took 0.039 seconds)

    COMPOSITIONS AND METHOD FOR ANTI-SICKLING OF RED BLOOD CELLS IN SICKLE CELL DISEASE
    41.
    发明申请
    COMPOSITIONS AND METHOD FOR ANTI-SICKLING OF RED BLOOD CELLS IN SICKLE CELL DISEASE 有权
    用于在镰状细胞疾病中防止红血球细胞的组合物和方法

    公开(公告)号：US20160222137A1

    公开(公告)日：2016-08-04

    申请号：US15008947

    申请日：2016-01-28

    Applicant: Shaker A. Mousa

    Inventor： Shaker A. Mousa

    IPC: C08B37/00 ,  A61K9/48 ,  A61K9/19 ,  A61K31/727

    CPC classification number: C08B37/0075 ,  A61K9/19 ,  A61K9/5123 ,  A61K31/727 ,  A61K45/06 ,  C08B37/003

    Abstract: A nano-composition that includes nanoparticles, a method of forming the nano-composition, and a method of using the composition. The nanoparticles include a polycationic polymer ionically bonded to one or more polyanionic Glycosaminoglycans (GAGs), wherein the polycationic polymer is chitosan, methylated chitosan, poly L-Lysine, or poly L-Arginine.

    Abstract translation: 包括纳米颗粒的纳米组合物，形成纳米组合物的方法和使用该组合物的方法。 纳米颗粒包括离子键合到一个或多个聚阴离子糖胺聚糖（GAG）的聚阳离子聚合物，其中聚阳离子聚合物是壳聚糖，甲基化壳聚糖，聚L-赖氨酸或聚L-精氨酸。

    Formulations of Factor VIIa inhibitors and utility
    42.
    发明授权
    Formulations of Factor VIIa inhibitors and utility 有权
    因子VIIa抑制剂和效用的制剂

    公开(公告)号：US08980823B2

    公开(公告)日：2015-03-17

    申请号：US13935665

    申请日：2013-07-05

    Applicant: Shaker A. Mousa

    Inventor： Shaker A. Mousa

    IPC: A61K38/00 ,  A61K38/05 ,  C07K14/755 ,  A61K47/48 ,  A61K9/50 ,  A61K31/195 ,  A61K31/4245 ,  A61K31/437 ,  C12N9/64 ,  A61K38/48

    CPC classification number: A61K47/48315 ,  A61K9/5031 ,  A61K9/5036 ,  A61K31/195 ,  A61K31/4245 ,  A61K31/437 ,  A61K38/4846 ,  A61K47/645 ,  A61K47/6929 ,  C12N9/6437

    Abstract: A method for treating a subject, such as a human patient, having a vascular disorder. The treatment method administers a therapeutic effective amount of a nanoparticle or a chemical structure to the subject to treat the disorders. The nanoparticle includes a poly L-arginine polymer and a Factor VIIa inhibitor conjugated to, or encapsulated in, the poly L-arginine polymer. The chemical structure includes a Factor VIIa inhibitor that includes at least one nitric oxide (NO) donor. The disorder may be sickle cell disease; stimulated or pathological angiogenesis associated disorders, cancer, ocular angiogenesis-mediated disorders such as diabetic retinopathy and macular degeneration, coagulation and/or platelet activation-associated disorders, pulmonary hypertension, or combinations thereof.

    Abstract translation: 用于治疗患有血管病症的受试者例如人类患者的方法。 治疗方法向受试者施用治疗有效量的纳米颗粒或化学结构以治疗疾病。 纳米颗粒包括聚L-精氨酸聚合物和与聚L-精氨酸聚合物缀合或封装的因子VIIa抑制因子。 该化学结构包括包含至少一种一氧化氮（NO）供体的因子VIIa抑制剂。 该病可能是镰状细胞病; 刺激或病理性血管生成相关疾病，癌症，眼血管生成介导的病症如糖尿病性视网膜病变和黄斑变性，凝血和/或血小板活化相关疾病，肺动脉高压或其组合。

    Silver nanoparticles as anti-microbial
    45.
    发明授权
    Silver nanoparticles as anti-microbial 有权
    银纳米颗粒作为抗菌剂

    公开(公告)号：US08314078B2

    公开(公告)日：2012-11-20

    申请号：US12796907

    申请日：2010-06-09

    Applicant: Shaker A. Mousa ,  Robert J. Linhardt

    Inventor： Shaker A. Mousa ,  Robert J. Linhardt

    IPC: A61K31/70 ,  C07H1/00 ,  C07H5/04

    CPC classification number: A61K31/727 ,  A01N59/16 ,  A61K9/5115 ,  A61K31/726 ,  A61K31/728 ,  A61K33/38 ,  A61K45/06 ,  A61K47/6923 ,  A61L15/46 ,  A61L26/0066 ,  A61L27/446 ,  A61L27/54 ,  A61L29/126 ,  A61L29/16 ,  A61L31/128 ,  A61L31/16 ,  A61L2300/104 ,  A61L2300/236 ,  A61L2300/624 ,  A61L2400/12 ,  B82Y5/00 ,  C08B37/0075 ,  C08L5/08 ,  C08L5/10 ,  A01N25/34 ,  A01N43/16 ,  A01N2300/00 ,  A61K2300/00

    Abstract: A silver nanocomposite, a formation method for forming the silver nanocomposite, and an application method utilizing the silver nanocomposite. The silver nanocomposite includes a silver nanoparticle conjugated to a glycosaminoglycan (GAG) or glucose. The formation method includes chemically reacting silver nitrate with a reducing agent to form a silver nanoparticle conjugated to the reducing agent of a GAG or glucose. The application method may include topically applying the silver nanocomposite to a wound or burn as an anti-microbial with respect to an antibiotic-resistant genotype in the wound or burn, wherein the silver nanocomposite topically applied includes the silver nanoparticle conjugated to the GAG of 2,6-diaminopyridinyl heparin (DAPHP) or hyaluronan (HA). The application method may include applying the silver nanocomposite as a coating to plastic, a catheter, or a surgical tool, wherein the silver nanocomposite applied as the coating includes the silver nanoparticle conjugated to the GAG of DAPHP.

    Abstract translation: 银纳米复合材料，形成银纳米复合材料的形成方法和利用银纳米复合材料的涂布方法。 银纳米复合材料包括与糖胺聚糖（GAG）或葡萄糖缀合的银纳米颗粒。 形成方法包括使硝酸银与还原剂化学反应以形成与GAG或葡萄糖的还原剂缀合的银纳米颗粒。 施用方法可以包括将伤口上的银纳米复合材料局部施用作为抗生素抗性基因型在伤口或烧伤中作为抗微生物剂，其中局部施用的银纳米复合材料包括与GAG缀合的银纳米颗粒2 ，6-二氨基吡啶基肝素（DAPHP）或透明质酸（HA）。 应用方法可以包括将银纳米复合物作为涂层施用于塑料，导管或外科工具，其中作为涂层施用的银纳米复合材料包括与DAPHP的GAG缀合的银纳米颗粒。

    Inhibition of angiogenesis by peptide analogs of high molecular weight kininogen domain 5
    50.
    发明授权
    Inhibition of angiogenesis by peptide analogs of high molecular weight kininogen domain 5 失效
    通过高分子量激肽原结构域的肽类似物抑制血管生成5

    公开(公告)号：US06284726B1

    公开(公告)日：2001-09-04

    申请号：US09612126

    申请日：2000-07-07

    Applicant: Robert W. Colman ,  Shaker A. Mousa

    Inventor： Robert W. Colman ,  Shaker A. Mousa

    IPC: A61K3800

    CPC classification number: C07K14/8139 ,  A61K38/00

    Abstract: Peptide analogs of the high molecular weight kininogen domain 5 are potent inhibitors of angiogenesis. The peptides have the formula X1-(HGLGHGHEQQHGKGH)-X2  (I) wherein X1 is from zero to 25 amino acids; X2 is from zero to 60 amino acids. Methods of inhibiting endothelial cell proliferation and angiogenesis are provided.

    Abstract translation: 高分子量激肽原结构域5的肽类似物是血管生成的有效抑制剂。 肽具有X 1为0至25个氨基酸，X2为0至60个氨基酸。提供了抑制内皮细胞增殖和血管发生的方法。

Patent Agency Ranking